# Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)

> **NCT00425256** · PHASE2 · COMPLETED · sponsor: **Palatin Technologies, Inc**

## Conditions studied

- Sexual Arousal Disorder

## Interventions

- **DRUG:** Bremelanotide

## Key facts

- **NCT ID:** NCT00425256
- **Lead sponsor:** Palatin Technologies, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** — (—)
- **Last updated:** 2011-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00425256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00425256, "Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00425256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*